Sonoma Pharmaceuticals Stock (NASDAQ:SNOA)


RevenueOwnershipFinancialsChart

Previous Close

$2.94

52W Range

$2.40 - $16.00

50D Avg

$4.52

200D Avg

$3.94

Market Cap

$3.82M

Avg Vol (3M)

$206.84K

Beta

1.37

Div Yield

-

SNOA Company Profile


Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Jan 25, 2007

Website

SNOA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 24Mar 23Mar 22
Service And Royalty$422.00K--
Animal Care$2.20M--
Human Care$10.11M--
Shipping and Handling-$42.00K$52.00K
Service--$349.00K

Fiscal year ends in Mar 24 | Currency in USD

SNOA Financial Summary


Mar 24Mar 23Mar 22
Revenue$12.73M$13.27M$12.63M
Operating Income$-4.70M$-4.57M$-5.89M
Net Income$-4.83M$-5.15M$-5.09M
EBITDA$-4.70M$-4.45M$-6.57M
Basic EPS$-0.53$-1.52$-1.92
Diluted EPS$-0.53$-1.52$-1.92

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts


Q2 19Nov 09, 18 | 12:16 AM
Q1 19Aug 09, 18 | 5:00 PM
Q4 18Jun 14, 18 | 5:00 PM

Peer Comparison


TickerCompany
AKANAkanda Corp.
TKNOAlpha Teknova, Inc.
ACORAcorda Therapeutics, Inc.
SBFMSunshine Biopharma, Inc.
LFCRLifecore Biomedical, Inc.
UPCUniverse Pharmaceuticals INC
GHSIGuardion Health Sciences, Inc.
ALIMAlimera Sciences, Inc.
SHPHShuttle Pharmaceuticals Holdings, Inc.
DERMJourney Medical Corporation
PTPIPetros Pharmaceuticals, Inc.
SXTCChina SXT Pharmaceuticals, Inc.